An observational study in Hematologic Neoplasms, Sarcoma and Bone Neoplasms, sponsored by Technical University of Munich. Recruiting at 2 sites in Germany. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Technical University of Munich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2026, is one of 15 observational ones, reaches primary completion later than 9 of the 27 other live ones, and was the 65th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
Browse Hematologic Neoplasms studies →20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
CSL Behring · Sites in Germany, United States, Belgium and 8 more countries
Ages 18+
Technical University of Munich · Sites in Germany
Ages 18+
Kura Oncology, Inc. · Sites in Germany, United States, Australia and 14 more countries
Ages 18+
Swedish Orphan Biovitrum · Sites in Germany, United States, Canada and 5 more countries
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 8 wk–65 yrs
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 25 · Phase 3 13
First in 1995; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 186 across 322 observational studies indexed under Hematologic Neoplasms.
Median enrollment 91 across the 50 interventional studies, 450 across the 15 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 65 have an industry lead sponsor. The 10 most frequent:
Technical University of Munich is the lead sponsor of 323 studies on the registry; 61 are open to participants now.
Technical University of Munich has 3 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Hematologic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782373Swedish Orphan BiovitrumA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | 2026-12-30 |
| NCT07519811Technical University of MunichLLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) | 2026-12-31 |
| NCT03735992Universität Duisburg-EssenMind-body Medicine for Patients With Malignant Hematological Diseases | 2026-12-31 |
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT06645886Kumquat Biosciences Inc.A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests whether an artificial intelligence (AI) system that drafts tumor board recommendations performs as well on new cases as it did on archived cases. The system runs in shadow mode at three multidisciplinary tumor boards of TUM University Hospital rechts der Isar. For each case it drafts a recommendation before the board meets. The board does not see the draft, and the draft has no influence on patient care. After the meeting, each draft is compared with the board decision. The agreement rate is then compared with the rate measured on archived decisions of the same boards.
The system is a locally operated large language model (LLM) pipeline with retrieval-augmented generation. Its input is the case as presented to the board, with diagnosis, course, question and all patient documents dated before the board date. It retrieves guideline recommendations (Onkopedia and AWMF S3 guidelines in the version in force on the board date), laboratory values, precedent cases from the board archive and PubMed abstracts published before the board date. It then drafts a recommendation with justification. Each statement of the draft is linked to a verbatim quote from its source. All models run on local GPU servers of the hospital with no data retention beyond the immediate analysis, and no patient data are sent to external providers.
The study includes the hematology board, the orthopedics and sarcoma board and the head and neck board. For each case registered for a session, the system drafts a recommendation after the pre-board documents are pulled and before the session starts. Board members do not see the drafts. The decision pipeline (generator Gemma-4-31B at temperature 0) is frozen and versioned for the study period. The study uses routine clinical data only. Patients are not contacted, and no study-specific procedures are performed.
The draft is compared with the consensus decision in the board report. An LLM judge (GLM-5.3-Flash, majority of three votes) assigns both texts to one of seven decision categories: systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care and referral to the molecular tumor board. It also scores agreement in substance from 0 to 3 and records the direction of any disagreement. The judge was validated against clinician ratings on a sealed test set. The same prompt version is used to score the prospective cases and the retrospective reference sample, separately from any output that clinicians see.
The retrospective reference is the evaluation sample of archived decisions of the same three boards (about 2,000 cases, one per patient, drawn with a fixed seed and stratified by time). Patients who also appear in the prospective cohort are removed from the reference. The primary analysis tests non-inferiority of the prospective category match rate against the retrospective rate, pooled over the three boards, with a margin of 7.5 percentage points and a one-sided alpha of 0.025. The variance is cluster-robust for board sessions. A case without a draft counts as not concordant. Per-board results are reported descriptively with 95% confidence intervals. An exploratory component evaluates a trial-matching engine that proposes recruiting clinical trials per case.
In a subset of 30 to 50 cases per board, physicians rate the system draft against the board decision. This subset tests whether the agreement between judge and clinicians, measured retrospectively, also holds prospectively.
All cases registered for the hematology, orthopedics and sarcoma, and head and neck tumor boards of TUM University Hospital rechts der Isar during the study period. One case is one patient presentation on one board date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Excluded cases are counted and reported by reason.
Consecutive cases presented at the hematology tumor board of TUM University Hospital rechts der Isar.
Other: OnkoBot (shadow mode)
Consecutive cases presented at the orthopedics and sarcoma tumor board of TUM University Hospital rechts der Isar.
Other: OnkoBot (shadow mode)
Consecutive cases presented at the head and neck tumor board of TUM University Hospital rechts der Isar.
Other: OnkoBot (shadow mode)
A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.
Proportion of Cases With Category Match Between System Draft and Board Decision
Proportion of discussed cases in which the system draft and the board consensus decision fall into the same of seven decision categories (systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care, referral to the molecular tumor board). Overlap counts where either side carries a second category. Assessed by a pre-specified LLM judge (GLM-5.3-Flash, prompt V3, majority of three votes), pooled over the three boards. Tested for non-inferiority against the rate of the same system and judge on the retrospective reference sample of the same boards, margin 7.5 percentage points, one-sided alpha 0.025.
Time frame: Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases Rated Concordant or Partially Concordant
Category match with a substance score of at least 1 of 3 (concordant requires at least 2 of 3 on a primary-category match, 3 of 3 where only second categories overlap). Non-inferiority versus retrospective reference, margin 7.5 percentage points, tested after the primary outcome (hierarchical testing).
Time frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases Rated Concordant, Partially Concordant and Not Concordant
Proportion of cases rated concordant, partially concordant and not concordant by the LLM judge.
Time frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match per Board
Category match and concordant or partially concordant per board, with 95% confidence intervals, descriptive.
Time frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Discordant Cases by Direction of Disagreement
Among cases without category match, proportion in which the draft is more conservative, more aggressive or a different modality than the board decision.
Time frame: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match as Rated by Clinicians
In 30 to 50 cases per board, agreement between draft and board decision as rated by physicians who did not attend the session, and agreement between judge and clinicians on category match (percentage agreement, Cohen's kappa).
Time frame: Within 3 months after the board session
Proportion of Citations Verified Word for Word Against Their Source
Proportion of citations per case that verify word for word against their source, and proportion of cases in which every citation verifies.
Time frame: At draft generation, before the board session
Proportion of Cases With a Draft Completed Before the Board Session
Proportion of cases with a draft completed before the session starts, and generation time per case in minutes.
Time frame: At draft generation, before the board session
Number of Clinical Trials Shortlisted per Case by the Trial-Matching Engine
Number of trials shortlisted per case, proportion recruiting on the board date, rule-based error rate (wrong disease, line of therapy, setting or status) and clinician screening verdicts where given.
Time frame: At draft generation, before the board session
Plan to share: No — Individual participant data are routine clinical records that may not leave the hospital under the ethics approval and data protection concept. Aggregate results and the analysis code will be published.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.
Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 322. This study's planned 2 months is below that.
Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technical University of Munich →